

Angeion Corporation
350 Oak Grove Parkway
St. Paul, MN 55127 USA
Telephone: (651) 484-4874
Facsimile: (651) 484-4826



FOR IMMEDIATE RELEASE

***Angeion Corporation Launches Physician Office Program for COPD
and Asthma Management***

***Company to Help Physicians Earlier Diagnose Respiratory Diseases that Affect More
Than 25 Million Americans***

ST. PAUL, Minn. - (June 2, 2008) — Angeion Corporation (NASDAQ: ANGN) today announced that it has launched its Physician Office Program for chronic obstructive pulmonary disease (COPD) and asthma management. Through aggressive, targeted marketing efforts, Angeion will work to increase physician awareness of COPD and the company's non-invasive cardiorespiratory systems that facilitate early diagnosis—and treatment—of the condition.

COPD is characterized by progressive obstruction of the airflow of the lungs and increased shortness of breath—which is often not diagnosed until after some lung capacity is already lost. Diseases included under the umbrella of COPD include emphysema, chronic bronchitis, bronchiectasis and refractory asthma.

According to the COPD Foundation, an individual dies of COPD every 4 minutes in the United States. Currently, COPD is the fourth leading cause of death, and is expected to be the third leading cause by 2020. The Centers for Disease Control (CDC) estimates that COPD and asthma affect more than 25 million Americans and result in more than 20 million physician office visits every year. Moreover, another 25 million Americans are believed to be either undiagnosed or misdiagnosed. Worldwide, an estimated 600 million people suffer from COPD.

“COPD is insidious, and it’s affecting more and more people every year,” said Rodney A. Young, Angeion’s president and chief executive officer. “To date, Angeion’s chief focus has been on bringing our cardiorespiratory technology and expertise to the hospital market. With today’s announcement, we are broadening our approach across the healthcare continuum to reach more physicians who may see COPD patients. Through our Physician Office Program, it’s our goal to work with the medical community to better educate and equip all physicians, regardless of specialty, to quickly and accurately diagnose the condition so that it can be treated earlier—resulting in more lives saved and less financial stress on today’s healthcare system.”

According to Young, Angeion's Physician Office Program reflects the company's commitment to early COPD detection. Specific components of the program include:

- A significant marketing focus, redirecting existing resources to educate and inform physicians, from pulmonologists to general practitioners and internists, about COPD and Angeion's unique diagnostic product offering;
- A comprehensive suite of educational and sales collateral materials; and
- Cost-effective equipment leasing programs

Angeion's cardiorespiratory systems, and particularly its recently introduced Medical Graphics Platinum Elite™ Series plethysmograph, provide the ability to effectively measure pulmonary function in the diagnosis of airway diseases, including COPD. In doing so, physicians benefit from:

- Improved patient care—complete pulmonary diagnostic capability
- Enhanced practice management—effectively and timely management of patients increases patient retention; and
- Easy, rapid testing—physicians are able to perform a complete pulmonary function study in approximately 20 minutes.

Said Young, "Through our Physician Office Program we'll heighten awareness of COPD and give physicians the tools to quickly and effectively diagnose the disease, provide a new growth catalyst for the company, and most important, help save more lives."

About Angeion Corporation

Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Our actual results may differ materially depending on a variety of factors including: (i) our ability to successfully operate our business including our ability to develop, improve, and update our cardiorespiratory diagnostic products and successfully sell these products under the MedGraphics and New Leaf Fitness brand names into existing and new markets, (ii) our ability to establish our cost structure at a level that is appropriate to our near to mid-term revenue expectations that will enable us to increase revenues and profitability as opportunities

develop, (iii) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers, (iv) our ability to effectively manufacture and ship products in required quantities to meet customer demands, (v) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (vi) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products, (vii) our ability to protect our intellectual property, (viii) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures, and (ix) our dependence on third-party vendors.

Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2007.

Contact: William J. Kullback, SVP & Chief Financial Officer, (651) 766-3492

###